Harvard Bioscience (HBIO) Total Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has reported Total Current Liabilities for 17 consecutive years, with $24.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 55.09% year-over-year to $24.8 million in Q2 2026; TTM through Jun 2026 was $24.8 million, a 55.09% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 60.04% from the prior year.
• Total Current Liabilities was $24.8 million for Q2 2026 at Harvard Bioscience, up from $23.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $55.6 million in Q1 2025 and troughed at $21.4 million in Q3 2022.
• A 5-year average of $30.8 million and a median of $24.0 million in 2023 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 144.03% in 2025, down 60.04% in 2025.
• Over 5 years, Total Current Liabilities stood at $23.2 million in 2022, then climbed by 14.16% to $26.5 million in 2023, then soared by 107.06% to $55.0 million in 2024, then slumped by 60.04% to $22.0 million in 2025, then advanced by 12.9% to $24.8 million in 2026.
• The last three Total Current Liabilities figures came in at $24.8 million (Q2 2026), $23.9 million (Q1 2026), and $22.0 million (Q4 2025), per Business Quant data.